Neo-adjuvant and adjuvant chemotherapy of bladder cancer: Is there a role?

Annals of Oncology

Volumn 13, Issue SUPPL. 4, 2002, Pages 273-279

  Sternberg, C N ^a  

^a Vincenzo Pansadoro Foundation   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MOLECULAR MARKER; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; VINBLASTINE;

ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MULTIMODALITY CANCER THERAPY; ORGAN PRESERVATION; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUALITY OF LIFE; SIDE EFFECT; SURVIVAL TIME; TRANSURETHRAL RESECTION;

EID: 0036433277     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf670     Document Type: Article

References (56)

1. Sternberg CN, Calabró F. Chemotherapy and management of bladder tumors. Br J Urol 2000; 85: 599-610.
2. Lerner SP, Skinner E, Skinner DG. Radical cystectomy in regionally advanced bladder cancer. Urol Clin North Am 1992; 19: 713-723.
3. Sternberg CN, Calabró F. Neo-adjuvant chemotherapy in invasive bladder cancer. World J Urol 2001; 19: 94-98.
4. Sternberg CN, Raghavan D, Ohi Y. Neo-adjuvant and adjuvant chemotherapy in locally advanced disease: what are the effects on survival and prognosis? Int J Urol 1995; 2: 76-88.
5. International Collaboration of Trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 1999; 354: 533-540.
6. Machin D, Campbell MJ, Fayers PM, Pinol APY. Sample Size Tables for Clinical Studies. London: Blackwell 1997.
7. Natale RB, Grossman HB, Blumenstein B et al. SWOG 8710 (INT-0080): Randomized phase III trial of neoadjuvant M-VAC and cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. Proc Am Soc Clin Oncol 2001; 20: 2a (Abstr 3).
8. Sternberg CN, Parmar MK. Neo-adjuvant chemotherapy is not (yet) standard treatment for muscle invasive bladder cancer. J Clin Oncol 2001; 19 (Suppl 1): 21S-26S.
9. Parmar MK. Neoadjuvant chemotherapy in invasive bladder cancer. Trial Design Prog Clin Biol Res 1990; 353: 115-118.
10. Solsona E, Iborra. I, Ricos JV et al. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: long-term follow-up of a prospective study. J Urol 1998; 159: 95-99.
11. Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 2001; 19: 89-93.
12. Parmar MKB, Machin D. Survival Analysis: A Practical Approach. Chichester, UK: Wiley 1995.
13. Bassi P, Pagano F, Pappagallo G et al. Neo-adjuvant M-VAC of invasive bladder cancer: The GUONE multicenter phase III trial. Eur Urol 1998; 33 (Suppl 1): 142 (Abstr).
14. GISTV (Italian Bladder Cancer Study Group). Neoadjuvant treatment for locally advanced bladder cancer: a randomized prospective clinical trial. J Chemother 1996; 8 (Suppl. 4): 345-346.
15. Malmstrom PU, Rintala E, Wahlqvist R et al. Five-year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy. J Urol 1996; 155: 1903-1906.
16. Malmstrom PU, Rintala E, Wahlqvist R et al. and members of the Nordic Urothelial Cancer Group. Neoadjuvant cisplatin-methotrexate chemotherapy of invasive bladder cancer. Nordic Cystectomy Trial 2. Eur Urol 1999; 35 (Suppl. 2): 60 (Abstr 238).
17. Sternberg CN, Pansadoro V. Transitional cell carcinoma of the urinary tract: bladder preserving treatments: chemotherapy and conservative surgery. In Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS. Comprehensive Textbook of Genitourinary Oncology, 2nd edition. Philadelphia, PA: Lippincott Williams & Wilkins 2000; 496-505.
18. Sternberg CN, Pansadoro V, Calabró F et al. Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. Ann Oncol 1999; 10: 1301-1305.
19. Hall RR, Roberts JT, Marsh MM. Radical TUR and chemotherapy aiming at bladder preservation. Prog Clin Biol Res 1990; 353: 163-168.
20. Splinter TAW, Pavone-Macaluso M, Jacqmin D et al. European Organization for Reasearch and Treatment of Cancer Genitourinary Group phase 2 study of chemotherapy in stage T3-4N0-XM0 transitional cell cancer of the bladder: evaluation of clinical response. J Urol 1992; 148: 1793-1796.
21. Sternberg CN, Pansadoro V, Calabró F et al. Can we select patients for bladder preservation based upon response to chemotherapy? J Urol 2000; 163; 216 (Abstr).
22. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001; 19: 666-675.
23. Dalbagni G, Genega E, Hashibe M et al. Cystectomy for bladder cancer: a contemporary series. J Urol 2001; 165: 1111-1116.
24. Chang SS, Alberts G, Cookson MS, Smith JA Jr. Radical cystectomy is safe in elderly patients at high risk. J Urol 2001; 166: 938-941.
25. Tester W, Porter A, Asbell S. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG Protocol 85-12. Int J Radiat Oncol Biol Phys 1993; 25: 783-790.
26. Kachnic LA, Kaufman DS, Heney NM. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 1997; 15: 1022-1029.
27. Hussain MH, Glass TR, Forman J et al. Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. J Urol 2001; 165: 56-60.
28. Bassi P, Ferrante GD, Piazza N et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol 1999; 161: 1494-1497.
29. Vieweg J, Gschwend JE, Herr HW, Fair WR. Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol 1999; 161: 449-454.
30. Skinner DG, Daniels JR, Russell CA et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991; 145: 459-467.
31. Stockle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages PT3b, PT4a, PN1 and PN2): improved survival after radical cystectomy and three adjuvant cycles of chemotherapy results of a controlled prospective study. J Urol 1992; 148: 302-307.
32. Stockle M, Meyenburg W, Wellek S. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 1995; 153: 47-52.
33. Otto T, Börgemann C, Krege S et al. Adjuvant chemotherapy in locally advanced bladder cancer (PT3/PN1-2,M0): a phase III study. Eur Urol 2001; 39 (Suppl. 5): 147 (Abstr).
34. Sylvester R, Sternberg C. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann Oncol 2000; 11: 851-856.
35. Sternberg CN, Yagoda A, Scher HI et al. M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 1989; 64: 2448-2458.
36. Sternberg CN, de Mulder PHM, Schornagel JH et al. for the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. Randomized phase III trial of high dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer. Protocol No. 30924. J Clin Oncol 2001; 19: 2638-2646.
37. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-3077.
38. Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder. N Engl J Med 1994; 331: 1259-1264.
39. Cote RJ, Dunn MD, Chatterjee SJ et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998; 58: 1090-1094.
40. Williams SG, Gandour-Edwards R, Deitch AD et al. Differences in gene expression in muscle-invasive bladder cancer: a comparison of Italian and American patients. Eur Urol 2001; 39: 430-437.
41. Cote RJ, Esrig D, Groshen S et al. p53 and treatment of bladder cancer. Nature 1997; 385: 123-125.
42. McShane LM, Aamodt R, Cordon-Cardo C et al. Reproducibility of p53 immumohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. Clin Cancer Res 2000; 6: 1854-1864.
43. Wallace DM, Raghavan D, Kelly KA et al. Neo-adjuvant (preemptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 1991; 67: 608-615.
44. Coppin CM, Gospodarowicz MK, James K et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14: 2901-2907.
45. Martinez Pineiro JA, Gonzalez Martin M, Arocena F. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: prospective randomized phase III study. J Urol 1995; 153: 964-973.
46. Abol-Enein H, El Makresh M, El Baz M, Ghoneim M. Neo-adjuvant chemotherapy in treatment of invasive transitional bladder cancer: a controlled, prospective randomised study. Br J Urol 1997; 80 (Suppl. 2): 49.
47. Tester W, Caplan R, Heaney J. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of radiation therapy oncology group phase II trial 8802. J Clin Oncol 1996; 14: 119-126.
48. Shipley WU, Winter KA, Kaufman DS et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998; 16: 3576-3583.
49. Sauer R, Birkenhake S, Kühn R et al. Muscle-invasive bladder cancer: transurethral resection and radiochemotherapy as an organsparing treatment option. Petrovich Z, Baert L, Brady LW (eds): Carcinoma of the Bladder. Springer 1998; 205-214.
50. Sauer R, Rodel C. Biological selection for organ conservation. Eur J Cancer 2001; 37 (Suppl. 6): S286 (Abstr).
51. Housset M, Dufour B, Maulard-Durdux C et al. Concomitant fluorouracil (5-FU)-cisplatin (CDDP) and bifractionated split course radiation therapy (BSCRT) for invasive bladder cancer. Proc Am Soc Clin Oncol 1997; 16: 319a (Abstr).
52. Durdux C, Housset M, Dufour B. Altered fractionation in chemoradiation for bladder cancer. Eur J Cancer 2001; 37 (Suppl. 6): S286 (Abstr).
53. Logothetis CJ, Johnson DE, Chong C et al. Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol 1988; 6: 1590-1596.
54. Studer UE, Bacchi M, Biedermann C. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 1994; 152: 81-84.
55. Bono AV, Benvenuti C, Reali L et al. Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group. Prog Clin Biol Res 1989; 303: 533-540.
56. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996; 155: 495-499.